Alixia
Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
Vendors
0Third parties this company currently discloses, grouped by function when classified.
No disclosed vendors yet
Vendors appear only once a public disclosure or other published evidence names them.
Customers
0Companies whose current disclosures name this company as a vendor.
No observed customers yet
Customers appear when another company's current disclosure names this company as a vendor.
Potential customers
0Companies using another vendor in one of Alixia’s categories, excluding Alixia’s observed customers.
No potential customers found
Potential customers appear after Alixia has a category assignment and current vendor relationships can be compared.